SAMHD1 Research Digest — 2026-07-13¶
Generated by samhd1_monitor | Model: claude-sonnet-5
Summary: 6 papers evaluated | 1 high-relevance (≥7) | 4 medium (5–6) | 1 low (3–4) | 0 scored <3
🔴 High Relevance (Score 7–10)¶
Auto-added to Zotero (threshold ≥6)
Mitochondrial DNA and Mitochondrial-Derived Vesicles as Immunometabolic Modulators of Innate Immunosurveillance through Control of the Mitochondrial Permeability Transition Pore (from Mitochondrial cell biology / immunometabolism)
Patrycja Anna Glogowski; S. Nesci; Antonia Cugliari; F. Trombetti; M. Fabbri — Translational Insights 2026
Score: 8/10 | Pathways: cGAS-STING, NLRP3, VDAC1, NF-kB-IKK, POLG-mtDNA, treatment-target
This paper details the mPTP-mtDNA-NLRP3/cGAS-STING axis and mitochondrial quality control (mitophagy/MDVs) that directly parallels the BLUE/PURPLE mechanism loops (VDAC1-mediated mtDNA escape, ox-mtDNA, NLRP3 activation) central to the SAMHD1 A565T pathophysiology, though it does not mention SAMHD1 itself.
DOI: 10.53941/ti.2026.100010
🟡 Medium Relevance (Score 5–6)¶
Score ≥6 auto-added to Zotero; lower scores: review manually
METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation. (from Oncology (prostate cancer molecular biology))
Yang Ruifeng; Ge Qintao; Wu Fengyao; Long Manmei; Li Bingyu — Oncogene 2026
Score: 6/10 | Pathways: IRF7-metabolic, POLG-mtDNA, BIK-cancer, clinical-phenotype
This paper links IRF7 (a core interferon pathway transcription factor also relevant to SAMHD1 biology) to mitochondrial DNA maintenance (via DNA2) and mitophagy in prostate cancer, a phenotype tracked in the SAMHD1 family, though the mechanism (rRNA m6A/METTL5) is distinct from SAMHD1 dNTPase pathways.
DOI: 10.1038/s41388-026-03867-w
Design and Synthesis of Novel Isoflavene TANK-Binding Kinase 1 Inhibitors With Anti-Inflammatory Activity. (from medicinal chemistry/drug design)
Falasca Valerio; Jayasekara W Samantha N; Nardo Dominic De; Wenholz Daniel S; Ga — ChemMedChem 2026
Score: 6/10 | Pathways: NF-kB-IKK, treatment-target
TBK1 inhibitors targeting NF-κB and type I IFN signaling are directly relevant to the IKKε/TBK1 non-canonical NF-κB and IRF3/IFN-I axis described in the disease mechanism, offering a potential therapeutic strategy for the interferonopathy component.
DOI: 10.1002/cmdc.70376
Successful salvage treatment with baricitinib for macrophage activation syndrome complicating adult-onset Still's disease during interleukin-6 inhibition: a case report and literature review. (from Rheumatology)
Nishisaka Kazuma; Ueda Yo; Shirasugi Iku; Yamada Hirotaka; Okano Takaichi — Modern rheumatology case reports 2026
Score: 5/10 | Pathways: JAK-STAT, treatment-target, clinical-phenotype
Baricitinib (JAK1/2 inhibitor) treating hyperinflammatory macrophage activation syndrome via IL-6/IFN-gamma/GM-CSF overlaps with the IFN-I/JAK-STAT axis and NLRP3-driven hyperinflammation central to the SAMHD1 model, with direct treatment-target relevance despite lacking SAMHD1 linkage.
DOI: 10.1093/mrcr/rxag072
CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates a β-thalassemia model (from Hematology/gene therapy engineering)
Romina Marone; Rosalba Lepore; K. Paschoudi; Jessica Zuin; A. Sinopoli — bioRxiv 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery
Uses prime editing on CD34+ HSPCs to engineer epitope resistance for toxin-free conditioning, relevant as a myeloid/HSC gene-editing delivery advance analogous to future correction strategies for a het missense variant like SAMHD1 A565T, though not disease-specific.
DOI: 10.64898/2026.07.07.736903
🟢 Low Relevance (Score 3–4)¶
Potential specialty bridges — skim titles
Organ-resolved endothelial regulatory programs link aging and metabolic overload to vascular immune remodeling (from Vascular biology/aging endothelial genomics)
Masataka Yokoyama; A. Nakayama; Yuki Taki; Mingyang Chen; Yingbo Gong — bioRxiv 2026
Score: 4/10 | Pathways: JAK-STAT, IRF7-metabolic, other
This paper describes an IRF/STAT-centered type I IFN endothelial aging program and metabolic vascular remodeling, tangentially echoing IFN-I/JAK-STAT themes but without SAMHD1, NLRP3, cGAS-STING, or mitochondrial dNTP mechanisms central to the disease profile.
DOI: 10.64898/2026.07.02.736039
Pathway Coverage This Week¶
treatment-target: 3 papersNF-kB-IKK: 2 papersPOLG-mtDNA: 2 papersIRF7-metabolic: 2 papersclinical-phenotype: 2 papersJAK-STAT: 2 paperscGAS-STING: 1 papersNLRP3: 1 papersVDAC1: 1 papersBIK-cancer: 1 papersprime-editing: 1 papersgene-therapy-delivery: 1 papersother: 1 papers